Enhanced antitumor efficacy of cisplatin in combination with HemoHIM in tumor-bearing mice

Abstract

BackgroundAlthough cisplatin is one of the most effective chemotherapeutic agents, cisplatin alone does not achieve a satisfactory therapeutic outcome. Also cisplatin accumulation shows toxicity to normal tissues. In this study, we examined the possibility of HemoHIM both to enhance anticancer effect with cisplatin and to reduce the side effects of cisplatin in melanoma-bearing mice.MethodsHemoHIM was prepared by adding the ethanol-insoluble fraction to the total water extract of a mixture of 3 edible herbs, Angelica Radix, Cnidium Rhizoma and Paeonia Radix. Anticancer effects of HemoHIM with cisplatin were evaluated in melanoma-bearing mice. We used a Cr51-release assay to measure the activity of NK/Tc cell and ELISA to evaluate the production of cytokines.ResultsIn melanoma-bearing mice, cisplatin (4 mg/kg B.W.) reduced the size and weight of the solid tumors, and HemoHIM supplementation with cisplatin enhanced the decrease of both the tumor size (p < 0.1) and weight (p < 0.1). HemoHIM itself did not inhibit melanoma cell growth in vitro, and did not disturb the effects of cisplatin in vitro. However HemoHIM administration enhanced both NK cell and Tc cell activity in mice. Interestingly, HemoHIM increased the proportion of NK cells in the spleen. In melanoma-bearing mice treated with cisplatin, HemoHIM administration also increased the activity of NK cells and Tc cells and the IL-2 and IFN-γ secretion from splenocytes, which seemed to contribute to the enhanced efficacy of cisplatin by HemoHIM. Also, HemoHIM reduced nephrotoxicity as seen by tubular cell of kidney destruction.ConclusionHemoHIM may be a beneficial supplement during cisplatin chemotherapy for enhancing the anti-tumor efficacy and reducing the toxicity of cisplatin.

PLGA-encapsulated tea polyphenols enhance the&nbsp;chemotherapeutic efficacy of cisplatin against human cancer cells and mice bearing Ehrlich ascites carcinoma

“…TF/EGCG (100 µg/mouse intraperitoneally twice in one week), CDDP, and different doses of TF/EGCG-loaded PLGA-NPs (10 and 20 µg/mouse) with or without CDDP were administered to mice in groups 3-13 for 15 days. CDDP alone (100 µg/mouse) was given intraperitoneally on days 1, 7, and 14 (total three doses) 26 and in the combination treatment groups a 1/10th dose (10 µg/mouse) was given. Animals in all groups were examined daily for formation of ascites by measuring changes in body weight.…”

Evaluation of Nephroprotective and Immunomodulatory Activities of Antioxidants in Combination with Cisplatin against Murine Visceral Leishmaniasis

“…Cisplatin is known to boost the cytotoxic T-lymphocyte mediated antitumor immunity [7], [8]. Park et al [37] also showed that cisplatin treatment increased the levels of IFN-γ and IL-2. IL-10 has been suggested to play a role in counterbalancing the exacerbated polarized response that may develop following cure [38].…”

Cystatin C – A Fast and Reliable Biomarker for Glomerular Filtration Rate in Head and Neck Cancer Patients

“…Notably, investigations have shown that about 20% of acute renal failure cases among hospitalized patients are due to platinum-based chemotherapy [4,19,22,27]. Several authors agree that renal damage due to cisplatin is irreversible.…”